Vimseltinib (formerly DCC-3014; DCC3014) is a novel, oral and potent dual inhibitor of c-FMS (CSF-IR) and c-Kit with anticancerc, immune checkpoint-inhibitory and immunomodulatory effects. It inhibits c-FMS (CSF-IR) and c-Kit with IC50s of<0.01 μM and 0.1-1 μM. As an investigational inhibitor of CSF1R, Vimseltinib demonstrated encouraging preliminary efficacy and safety data in patients with TGCT and is currently being evaluated in a Phase 1/2 clinical study.

纯度：≥98%

CAS：1628606-05-2